Trial Profile

An Observational Long-Term Safety Surveillance of Participants from Corbus Sponsored Lenabasum Pivotal Clinical Trials

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 17 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenabasum (Primary)
Indications Cystic fibrosis; Dermatomyositis
Focus Adverse reactions
Sponsors Corbus Pharmaceuticals

Most Recent Events

16 Dec 2020 This trial has been completed in the United Kingdom according to European Clinical Trials Database record.
10 Nov 2020 This trial has been Discontinued in Germany and Discontinued in Hungary.
29 Oct 2020 This trial has been completed in Germany and Discontinued in Hungary.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com